Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Montelukast in Asthma Treatment in Croatia (CROSBI ID 209988)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Samaržija, Miroslav ; Jakopović, Marko ; Pavičić, Fadila ; Kukulj, Suzana ; Popović-Grle, Sanja Montelukast in Asthma Treatment in Croatia // Collegium antropologicum, 29 (2005), 2; 683-688

Podaci o odgovornosti

Samaržija, Miroslav ; Jakopović, Marko ; Pavičić, Fadila ; Kukulj, Suzana ; Popović-Grle, Sanja

engleski

Montelukast in Asthma Treatment in Croatia

The aim of this study was to determine the efficacy and safety of montelukast added to previous medication in the treatment of a mild and moderate asthma. Data were obtained via questionnaires given to the physicians and given further to their patients. Patients were divided in two groups, first followed 4 weeks (612 patients) and second followed 8 weeks (91 patients).We found out that there was a significant improvement in FEV1 (forced expiratory volume in first second) and general condition of patients and decreased number of salbutamol inhalations after using montelukast. In the second group of patients we find out the same significant improvement in FEV1, general condition and decrease in salbutamol inhalations after 4 weeks of using montelukast and further improvement after the next month of therapy. We conclude that montelukast is an efficient drug with little side effects and with a good compliance. Montelukast managed to achieve a good asthma control ; therefore it has a significant place in asthma therapy.

montelukast; asthma

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

29 (2)

2005.

683-688

objavljeno

0350-6134

Povezanost rada

Kliničke medicinske znanosti

Poveznice
Indeksiranost